UOC
PRAX icon

UBS O'Connor’s Praxis Precision Medicines PRAX Stock Holding History

UBS O'Connor’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$60.6K – 543
2024
Q3 		$60.6K Buy
+25,000
New +$1.35M ﹤0.01% 424

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

UBS O'Connor's PRAX Position: Q3 2025 in Review

UBS O'Connor sold out of Praxis Precision Medicines (PRAX) in Q3 2025, closing a stake of 21,892 shares — an estimated $921K sold.

UBS O'Connor first reported a position in PRAX in Q1 2022 and held it in 14 quarters. The position peaked at $2.21M in Q3 2024. 152 funds tracked by Wall St. Rank hold PRAX as of Q3 2025.

  • UBS O'Connor reported no remaining Praxis Precision Medicines position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 21,892 Praxis Precision Medicines shares in Q3 2025, an estimated $921K.
  • UBS O'Connor first reported a position in Praxis Precision Medicines in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Praxis Precision Medicines position peaked at $2.21M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.